Intervention not reported
Treatment failure · antiretroviral‐naïve individuals
The intervention showed no clear difference in treatment failure (low certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: central nervous system · antiretroviral‐naïve individuals
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).
1 finding from 1 review
Intervention not reported
Severe adverse events: gastrointestinal · antiretroviral‐naïve individuals
The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).
1 finding from 1 review
ACT use (percentage of children under 5 years receiving ACT on the same day or following day of fever onset) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT availability (percentage of outlets stocking ACTs for children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
ACT availability (percentage of outlets stocking at least one ACT for patients of any age) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
ACT price (change in ACT prices for children under 5 years)c · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
ACT market share (volume of ACTs purchased as a proportion of all antimalarials purchased; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
Use of older antimalarials (amodiaquine, sulphadoxine‐pyrimethamine; children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Adverse effects (such as the number of people receiving ACTs who do not have malaria) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT access (percentage of illness episodes treated with ACTs; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT targeting (percentage of ACT takers who are malaria positive; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
Remaining parasitaemic at 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT leads to lower remaining parasitaemic at 24 hours compared with CQ (high certainty).
1 finding from 1 review
Remaining febrile after 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT probably leads to lower remaining febrile after 24 hours compared with CQ (moderate certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in effective treatment of the blood stage parasite As assessed by:… compared with CQ (high certainty).
1 finding from 1 review
Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56/63 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with CQ (low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P probably leads to lower effective treatment of the blood stage parasite As assessed by:… compared with alternative ACTs (moderate certainty).
1 finding from 1 review
Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with alternative ACTs (low certainty).
1 finding from 1 review
Outcomes · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found